Substance / Medication

Etidronate

Overview

Active Ingredient
etidronate
RxNorm CUI
42682

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

7
Total Trials
1
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells George A, Hsieh Shu-Ching, Peterson Joan et al. · Cochrane Database Syst Rev · 2024
PMID: 38591743Meta-AnalysisFull text (PMC)
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells G A, Cranney A, Peterson J et al. · Cochrane Database Syst Rev · 2008
PMID: 18254018Meta-AnalysisFull text (PMC)
WITHDRAWN: Etidronate for treating and preventing postmenopausal osteoporosis.
Cranney A, Adachi J D, Griffith L et al. · Cochrane Database Syst Rev · 2007
PMID: 17636719Meta-Analysis
A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis.
Cranney A, Guyatt G, Krolicki N et al. · Osteoporos Int · 2001
PMID: 11303715Meta-Analysis
Etidronate for treating and preventing postmenopausal osteoporosis.
Cranney A, Welch V, Adachi J D et al. · Cochrane Database Syst Rev · 2001
PMID: 11687195Meta-Analysis
The effect of etidronate on choroidal neovascular activity in patients with pseudoxanthoma elasticum.
Risseeuw Sara, van Leeuwen Redmer, Imhof Saskia M et al. · PLoS One · 2020
PMID: 33079965RCTFull text (PMC)
Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum.
Bartstra Jonas W, de Jong Pim A, Kranenburg Guido et al. · Atherosclerosis · 2020
PMID: 31756632RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Etidronate (substance)
SNOMED CT
372908005
UMLS CUI
C0086268
RxNorm CUI
42682

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.